-

Eurofins Scientific Announces the Acquisition of Quasfar, Establishing a Presence in Colombia and Expanding the Presence of Eurofins Laboratories in Latin America

LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services, announces the completion of the acquisition of Quasfar.

Known as Eurofins Quasfar going forward, the laboratory represents the first Eurofins laboratory in Colombia and is a leading pharmaceutical, veterinary and cosmetic product testing laboratory, with over 26 years of experience, employing over 100 employees. Based in Bogotá, Colombia, the 1,680 m² laboratory is equipped with state-of-the-art testing equipment, technology and information platforms and systems, and is certified in Good Laboratory Practices for pharmaceutical quality control laboratories, under the guidelines of WHO Technical Report Series, No. 957, 2010 44th Report – Annex 1. With a focus on scientific training and R&D, the Quasfar team develops analytical methodologies that respond to customer and regulatory needs, with a commitment to exceptional quality management systems, and good laboratory, bioavailability and bioequivalence practices.

The origins of Eurofins’ presence in Brazil dates back to 2001, when Eurofins Genescan established its presence in Brazil, setting up an office in São Paulo/SP, shortly followed by the opening of a laboratory. Since then, the Eurofins network of companies has continued to expand in Brazil and Latin America, with more than 10 laboratories across 5 LATAM countries now operating across food, environmental, pharmaceutical, agroscience, and clinical diagnostics testing, as well as providing special consultancy services and audits.

With a proven history in providing support to the pharmaceutical sector in Colombia, the acquisition of Quasfar strengthens the Eurofins network’s support to the pharmaceutical industry in Latin America, through the provision of R&D and supporting evaluation in the early stages of pharmaceutical product development, with the highest quality standards and TAT.

Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 61,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Eurofins Quasfar:
Bogotá- based Eurofins Quasfar is a state-of-the-art laboratory, offering a broad analytical testing portfolio to the pharmaceutical, veterinary and cosmetic segments, and recognised for its expertise in developing complex analytical methodologies with diverse techniques to meet customer and regulatory needs.

Contacts

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

More News From Eurofins Scientific

Eurofins Announces the Successful Closing of Its Acquisition of SYNLAB’s Clinical Diagnostics Operations in Spain

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, with a rapidly developing presence in highly specialised and molecular clinical diagnostics testing and in-vitro diagnostics products, announces the successful closing of the acquisition of SYNLAB’s clinical diagnostics operations in Spain and the transfer of operations to Eurofins, which took place on 31 March 2025. SYNLAB’s clinical diagnostics operations in Spain...

Eurofins: Purchases of Own Shares from March 24th to March 28th 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS 529900JEHFM47DYY3S57 24/03/2025 FR0014000MR3 112,452 51.0468 XPAR EUROFINS 529900JEHFM47DYY3S57 24/03/2025 FR0014000MR3 33,548 50.9670 CEUX EUROFINS 529900JEHFM47DYY3S57 24/03/2025 FR0014000MR3 2,000...

Eurofins Successfully Prices New Hybrid Bonds of €400m

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Eurofins Scientific (EUFI.PA, rated Baa3 by Moody’s and BBB- by Fitch), a global leader in bioanalytical testing, announces that it has successfully raised €400m in its latest Euro hybrid bond public issuance. The transaction was well received and more than 3x times over-subscribed. This new series of bonds has no specified maturity date and is accounted for as 100% equity according to international financial reporting standard...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.